摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-phenyl-4-trifluoromethanesulfonyloxy-thieno[2,3-b]pyridin-6-yl)-acetic acid ethyl ester | 890124-98-8

中文名称
——
中文别名
——
英文名称
(3-phenyl-4-trifluoromethanesulfonyloxy-thieno[2,3-b]pyridin-6-yl)-acetic acid ethyl ester
英文别名
(3-Phenyl-4-trifluoromethanesulfonyloxy-thieno[2,3-b]pyridin-6-yl)-acetic acid ethyl ester;ethyl 2-[3-phenyl-4-(trifluoromethylsulfonyloxy)thieno[2,3-b]pyridin-6-yl]acetate
(3-phenyl-4-trifluoromethanesulfonyloxy-thieno[2,3-b]pyridin-6-yl)-acetic acid ethyl ester化学式
CAS
890124-98-8
化学式
C18H14F3NO5S2
mdl
——
分子量
445.44
InChiKey
OPRHLVJPFGQDIT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    29
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    119
  • 氢给体数:
    0
  • 氢受体数:
    10

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds
    申请人:Ford John
    公开号:US20060183768A1
    公开(公告)日:2006-08-17
    The invention provides compounds of the formula: wherein R1 is aryl, heteroaryl, cycloalkyl or alkyl; R2 is H, alkyl, nitro, C0 2 R7, CONR5R6 or halo; R3 and R4 are H, NR5R6, NC(O)R7, halo, trifluromethyl, alkyl, CONR5R6, CO 2 R7, nitrile or alkoxy; R5 and R6 may be the same or different and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R5 and R6 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S; R7 is H or alkyl; A is H, halo, or a group of formula X-L-Y; X is O, S or NR8; R8 is H or alkyl; L is (CH 2 ) n , where n is 0, 1, 2, 3 or 4; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; the products of mono- and di-oxidation of sulphur and/or mono-oxidation of nitrogen moieties in compounds of formula I; or a pharmaceutically acceptable salt thereof. These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.
    本发明提供了以下化合物: 其中,R1为芳基、杂环芳基、环烷基或烷基; R2为H、烷基、硝基、C02R7、CONR5R6或卤素; R3和R4为H、NR5R6、NC(O)R7、卤素、三氟甲基、烷基、CONR5R6、CO2R7、腈或烷氧基; R5和R6可以相同也可以不同,可以是H、烷基、芳基、杂环芳基或环烷基;或者R5和R6可以一起形成一个饱和、不饱和或部分饱和的4至7成员环,其中该环可以选择性地包含一个或多个进一步的杂原子,所选择的杂原子为N、O或S; R7为H或烷基; A为H、卤素或公式X-L-Y的基团; X为O、S或NR8; R8为H或烷基; L为(CH2)n,其中n为0、1、2、3或4; Y为芳基、杂环基、烷基、烯丙基或环烷基; 化合物I的硫单氧化物和/或氮单氧化物的单一和双重氧化产物;或其药学上可接受的盐。这些化合物可用作钾离子通道的抑制剂,因此可用于治疗包括心律失常和2型糖尿病在内的各种疾病。
  • Thieno[2,3-b]pyridines as Potassium Channel Inhibitors
    申请人:FORD John
    公开号:US20100041695A1
    公开(公告)日:2010-02-18
    The invention provides compounds of the formula: wherein R1 is aryl, heteroaryl, cycloalkyl or alkyl; R2 is H, alkyl, nitro, CO 2 R7, CONR5R6 or halo; R3 and R4 are H, NR5R6, NC(O)R7, halo, trifluoromethyl, alkyl, CONR5R6, CO 2 R7, nitrile or alkoxy; R5 and R6 may be the same or different and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R5 and R6 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S; R7 is H or alkyl; A is H, halo, or a group of formula X-L-Y; X is O, S or NR8; R8 is H or alkyl; L is (CH 2 ) n , where n is 0, 1, 2, 3 or 4; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; the products of mono- and di-oxidation of sulphur and/or mono-oxidation of nitrogen moieties in compounds of formula I; or a pharmaceutically acceptable salt thereof. These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.
    该发明提供了以下式子的化合物:其中,R1是芳基,杂环芳基,环烷基或烷基;R2是H,烷基,硝基,CO2R7,CONR5R6或卤素;R3和R4是H,NR5R6,NC(O)R7,卤素,三氟甲基,烷基,CONR5R6,CO2R7,腈或烷氧基;R5和R6可能相同或不同,可以是H,烷基,芳基,杂环芳基或环烷基;或者R5和R6可以共同形成饱和的、不饱和的或部分饱和的4到7成员环,其中该环可以选择地包含一个或多个来自N、O或S的进一步杂原子;R7是H或烷基;A是H、卤素或公式X-L-Y的基团;X是O、S或NR8;R8是H或烷基;L是(CH2)n,其中n为0、1、2、3或4;而Y是芳基、杂环基、烷基、烯基或环烷基;该式I中硫单氧化物和/或氮单氧化物基团的单氧化和二氧化产物;或其药学上可接受的盐。这些化合物可用作钾离子通道的抑制剂,因此对于治疗包括心律不齐和2型糖尿病在内的各种疾病是有用的。
  • Thieno[2,3-B] pyridines as potassium channel inhibitors
    申请人:Xention Limited
    公开号:US07576212B2
    公开(公告)日:2009-08-18
    The invention provides compounds of the formula: wherein R1 is aryl, heteroaryl, cycloalkyl or alkyl; R2 is H, alkyl, nitro, CO2R7, CONR5R6 or halo; R3 and R4 are H, NR5R6, NC(O)R7, halo, trifluromethyl, alkyl, CONR5R6, CO2R7, nitrile or alkoxy; R5 and R6 may be the same or different and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R5 and R6 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S; R7 is H or alkyl; A is H, halo, or a group of formula X-L-Y; X is O, S or NR8; R8 is H or alkyl; L is (CH2)n, where n is 0, 1, 2, 3 or 4; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; the products of mono- and di-oxidation of sulphur and/or mono-oxidation of nitrogen moieties in compounds of formula I; or a pharmaceutically acceptable salt thereof. These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.
    本发明提供了以下式子的化合物:其中R1是芳基、杂环芳基、环烷基或烷基;R2是H、烷基、硝基、CO2R7、CONR5R6或卤素;R3和R4是H、NR5R6、NC(O)R7、卤素、三氟甲基、烷基、CONR5R6、CO2R7、腈或烷氧基;R5和R6可以相同也可以不同,可以是H、烷基、芳基、杂环芳基或环烷基;或者R5和R6可以共同形成一个饱和、不饱和或部分饱和的4到7成员环,其中所述环可以选择包含一个或多个来自N、O或S的进一步杂原子;R7是H或烷基;A是H、卤素或式子X-L-Y的基团;X是O、S或NR8;R8是H或烷基;L是(CH2)n,其中n为0、1、2、3或4;Y是芳基、杂环基、烷基、烯基或环烷基;化合物I中硫和/或氮基团的单氧化和双氧化产物;或其药学上可接受的盐。这些化合物可用作钾离子通道的抑制剂,因此可用于治疗包括心律失常和2型糖尿病在内的各种疾病。
  • Thieno[2 3-b]pyridines as potassium channel inhibitors
    申请人:Xention Limited
    公开号:US08193215B2
    公开(公告)日:2012-06-05
    The invention provides compounds of the formula: wherein R1 is aryl, heteroaryl, cycloalkyl or alkyl; R2 is H, alkyl, nitro, CO2R7, CONR5R6 or halo; R3 and R4 are H, NR5R6, NC(O)R7, halo, trifluromethyl, alkyl, CONR5R6, CO2R7, nitrile or alkoxy; R5 and R6 may be the same or different and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R5 and R6 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S; R7 is H or alkyl; A is H, halo, or a group of formula X-L-Y; X is O, S or NR8; R8 is H or alkyl; L is (CH2)n, where n is 0, 1, 2, 3 or 4; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; the products of mono- and di-oxidation of sulphur and/or mono-oxidation of nitrogen moieties in compounds of formula I; or a pharmaceutically acceptable salt thereof. These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.
    该发明提供了以下式子的化合物: 其中,R1是芳基,杂环芳基,环烷基或烷基; R2是H,烷基,硝基,CO2R7,CONR5R6或卤素; R3和R4是H,NR5R6,NC(O)R7,卤素,三氟甲基,烷基,CONR5R6,CO2R7,腈或烷氧基; R5和R6可以相同也可以不同,可以是H,烷基,芳基,杂环芳基或环烷基;或者R5和R6可以共同形成一个饱和的、不饱和的或部分饱和的4至7成员环,其中该环可以选择性地包括一个或多个来自N、O或S的进一步杂原子; R7是H或烷基; A是H,卤素或式子X-L-Y的基团; X是O,S或NR8; R8是H或烷基; L是(CH2)n,其中n为0、1、2、3或4; Y是芳基、杂环基、烷基、烯基或环烷基; 该式I化合物中硫和/或氮基团的单氧化和双氧化产物;或其药学上可接受的盐。 这些化合物可用作钾离子通道抑制剂,因此对于治疗各种病症,包括心律失常和2型糖尿病非常有用。
  • THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS
    申请人:Xention Discovery Limited
    公开号:EP1879899A1
    公开(公告)日:2008-01-23
查看更多

同类化合物

钠3-氨基-4,6-二甲基噻吩并[2,3-b]吡啶-2-羧酸酯 脱乙酰基2-O-叔-丁基二甲基硅烷基普拉格雷 羟基(噻吩并[2,3-b]吡啶-3-基)乙腈 盐酸噻氯匹定 甲基4-溴7-氧-6,7-二氢噻吩并[2,3-C]吡啶-2-羧酸酯 甲基3-甲基噻吩并[2,3-c]吡啶-2-羧酸酯 甲基3-氨基噻吩并[2,3-c]吡啶-2-羧酸酯 甲基3-氨基-4-(二甲基氨基)噻吩并[2,3-b]吡啶-2-羧酸酯 甲基3-氨基-4,5,6-三甲基噻吩并[2,3-b]吡啶-2-羧酸酯 甲基2,4-二甲基噻吩并[3,4-b]吡啶-7-羧酸酯 替诺立定 普拉格雷羟基硫内酯 普拉格雷盐酸盐 普拉格雷杂质III 普拉格雷杂质1 普拉格雷杂质 普拉格雷 外消旋-2-(2-氯苯基)-(6,7-二氢-4H-噻吩并[3,2-c]吡啶-5-基)乙腈 噻氯吡啶杂质F 噻氯吡啶杂质E 噻氯匹定杂质8 噻氯匹定N-氧化物 噻氯匹定3-氯异构体 噻氯匹定 噻氯匹丁-d4 噻吩并吡啶酮 噻吩并吡啶-2-甲酸甲酯 噻吩并[3,4-b]吡啶-5,7-二酮 噻吩并[3,2:3,4]环戊二烯并[1,2-b]吖丙因(9CI) 噻吩并[3,2-c]吡啶-3-胺 噻吩并[3,2-c]吡啶-3-羧醛 噻吩并[3,2-c]吡啶-2-羧酸甲酯 噻吩并[3,2-c]吡啶-2-羧酸 噻吩并[3,2-c]吡啶-2-基硼酸 噻吩并[3,2-c]吡啶 噻吩并[3,2-b]吡啶-7-羧酸 噻吩并[3,2-b]吡啶-6-醇 噻吩并[3,2-b]吡啶-6-胺 噻吩并[3,2-b]吡啶-6-羧酸甲酯 噻吩并[3,2-b]吡啶-6-羧酸 噻吩并[3,2-b]吡啶-5-羧酸 噻吩并[3,2-b]吡啶-3-胺 噻吩并[3,2-b]吡啶-2-羧酸甲酯 噻吩并[3,2-b]吡啶-2-羧酸 噻吩并[3,2-b]吡啶-2-甲醇 噻吩并[3,2-C]吡啶-2-硼酸频那醇酯 噻吩并[3,2-B]吡啶-3-羧酸甲酯 噻吩并[2,3-c]吡啶-7-胺 噻吩并[2,3-c]吡啶-7-羧酸甲酯 噻吩并[2,3-c]吡啶-7-羧酸